Literature DB >> 19118032

Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex.

Ioannis P Trougakos1, Magda Lourda, Marianna H Antonelou, Dimitris Kletsas, Vassilis G Gorgoulis, Issidora S Papassideri, Yonglong Zou, Lukas H Margaritis, David A Boothman, Efstathios S Gonos.   

Abstract

PURPOSE: Secretory clusterin (sCLU)/apolipoprotein J is an extracellular chaperone that has been functionally implicated in DNA repair, cell cycle regulation, apoptotic cell death, and tumorigenesis. It exerts a prosurvival function against most therapeutic treatments for cancer and is currently an antisense target in clinical trials for tumor therapy. However, the molecular mechanisms underlying its function remained largely unknown. EXPERIMENTAL
DESIGN: The molecular effects of small interfering RNA-mediated sCLU depletion in nonstressed human cancer cells were examined by focusing entirely on the endogenously expressed sCLU protein molecules and combining molecular, biochemical, and microscopic approaches.
RESULTS: We report here that sCLU depletion in nonstressed human cancer cells signals stress that induces p53-dependent growth retardation and high rates of endogenous apoptosis. We discovered that increased apoptosis in sCLU-depleted cells correlates to altered ratios of proapoptotic to antiapoptotic Bcl-2 protein family members, is amplified by p53, and is executed by mitochondrial dysfunction. sCLU depletion-related stress signals originate from several sites, because sCLU is an integral component of not only the secretory pathway but also the nucleocytosolic continuum and mitochondria. In the cytoplasm, sCLU depletion disrupts the Ku70-Bax complex and triggers Bax activation and relocation to mitochondria. We show that sCLU binds and thereby stabilizes the Ku70-Bax protein complex serving as a cytosol retention factor for Bax.
CONCLUSIONS: We suggest that elevated sCLU levels may enhance tumorigenesis by interfering with Bax proapoptotic activities and contribute to one of the major characteristics of cancer cells, that is, resistance to apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19118032      PMCID: PMC4483278          DOI: 10.1158/1078-0432.CCR-08-1805

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  38 in total

1.  Synthesis and functional analyses of nuclear clusterin, a cell death protein.

Authors:  Konstantin S Leskov; Dmitry Y Klokov; Jing Li; Timothy J Kinsella; David A Boothman
Journal:  J Biol Chem       Date:  2003-01-24       Impact factor: 5.157

2.  A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.

Authors:  Kim N Chi; Elizabeth Eisenhauer; Ladan Fazli; Edward C Jones; S Larry Goldenberg; Jean Powers; Dongsheng Tu; Martin E Gleave
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

Review 3.  Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer.

Authors:  B Shannan; M Seifert; K Leskov; J Willis; D Boothman; W Tilgen; J Reichrath
Journal:  Cell Death Differ       Date:  2006-01       Impact factor: 15.828

4.  Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis.

Authors:  Valérie Devauchelle; Abdellatif Essabbani; Gonzague De Pinieux; Stéphane Germain; Léa Tourneur; Sylvie Mistou; Florence Margottin-Goguet; Philippe Anract; Henri Migaud; Dominique Le Nen; Thierry Lequerré; Alain Saraux; Maxime Dougados; Maxime Breban; Catherine Fournier; Gilles Chiocchia
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

5.  Interaction of transforming growth factor beta receptors with apolipoprotein J/clusterin.

Authors:  K B Reddy; M C Karode; A K Harmony; P H Howe
Journal:  Biochemistry       Date:  1996-01-09       Impact factor: 3.162

6.  Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress.

Authors:  I Viard; P Wehrli; L Jornot; R Bullani; J L Vechietti; J A Schifferli; J Tschopp; L E French
Journal:  J Invest Dermatol       Date:  1999-03       Impact factor: 8.551

Review 7.  Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases.

Authors:  Ioannis P Trougakos; Efstathios S Gonos
Journal:  Free Radic Res       Date:  2006-12

8.  Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1.

Authors:  Maurizio Scaltriti; Anna Santamaria; Rosanna Paciucci; Saverio Bettuzzi
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

Review 9.  Stress induction of GRP78/BiP and its role in cancer.

Authors:  Jianze Li; Amy S Lee
Journal:  Curr Mol Med       Date:  2006-02       Impact factor: 2.222

10.  Apolipoprotein J: structure and tissue distribution.

Authors:  H V de Silva; J A Harmony; W D Stuart; C M Gil; J Robbins
Journal:  Biochemistry       Date:  1990-06-05       Impact factor: 3.162

View more
  62 in total

1.  CRM1 protein-mediated regulation of nuclear clusterin (nCLU), an ionizing radiation-stimulated, Bax-dependent pro-death factor.

Authors:  Konstantin S Leskov; Shinako Araki; John-Paul Lavik; Jose A Gomez; Vivian Gama; Efstathios S Gonos; Ioannis P Trougakos; Shigemi Matsuyama; David A Boothman
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

2.  Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.

Authors:  Bin Zhong; David A Sallman; Danielle L Gilvary; Daniele Pernazza; Eva Sahakian; Dillon Fritz; Jin Q Cheng; Ioannis Trougakos; Sheng Wei; Julie Y Djeu
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

Review 3.  Proteomic approaches and identification of novel therapeutic targets for alcoholism.

Authors:  Giorgio Gorini; R Adron Harris; R Dayne Mayfield
Journal:  Neuropsychopharmacology       Date:  2013-07-31       Impact factor: 7.853

Review 4.  Clusterin and chemoresistance.

Authors:  Julie Y Djeu; Sheng Wei
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

5.  Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.

Authors:  Amina Zoubeidi; Kim Chi; Martin Gleave
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

6.  Interaction of clusterin and matrix metalloproteinase-9 and its implication for epithelial homeostasis and inflammation.

Authors:  Shinwu Jeong; Dolena R Ledee; Gabriel M Gordon; Tatsuo Itakura; Nitin Patel; Aaron Martin; M Elizabeth Fini
Journal:  Am J Pathol       Date:  2012-03-20       Impact factor: 4.307

7.  PTCD1 Is Required for Mitochondrial Oxidative-Phosphorylation: Possible Genetic Association with Alzheimer's Disease.

Authors:  Daniel Fleck; Lilian Phu; Erik Verschueren; Trent Hinkle; Mike Reichelt; Tushar Bhangale; Benjamin Haley; Yuanyuan Wang; Robert Graham; Donald S Kirkpatrick; Morgan Sheng; Baris Bingol
Journal:  J Neurosci       Date:  2019-04-04       Impact factor: 6.167

Review 8.  Protective molecular mechanisms of clusterin against apoptosis in cardiomyocytes.

Authors:  Rodrigo Martins Pereira; Rania A Mekary; Kellen Cristina da Cruz Rodrigues; Chadi Pellegrini Anaruma; Eduardo Rochete Ropelle; Adelino Sanchez Ramos da Silva; Dennys Esper Cintra; José Rodrigo Pauli; Leandro Pereira de Moura
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

9.  Resveratrol, an activator of SIRT1, improves ER stress by increasing clusterin expression in HepG2 cells.

Authors:  Jinmi Lee; Seok-Woo Hong; Hyemi Kwon; Se Eun Park; Eun-Jung Rhee; Cheol-Young Park; Ki-Won Oh; Sung-Woo Park; Won-Young Lee
Journal:  Cell Stress Chaperones       Date:  2019-06-10       Impact factor: 3.667

Review 10.  The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases.

Authors:  S Park; K W Mathis; I K Lee
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.